EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Research Progress on Targeted Therapies for Pemphigus Vulgaris and Bullous Pemphigoid: Mechanisms, Opportunities and Challenges

Wang-Fei Mo, Ya-Gang Zuo iD

International Journal of Molecular Sciences · 2026

DOI: 10.3390/ijms27198779 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Wang-Fei Mo und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medica…. Hauptthemen laut MEDLINE: Pemphigus, Pemphigoid, Bullous, Molecular Targeted Therapy. Die Arbeit nennt 222 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Autoimmune bullous diseases (AIBDs) are a group of severe disorders characterized by autoantibodies that attack structural proteins within the skin/mucosa, leading to blister and bullae formation. Pemphigus vulgaris (PV) and bullous pemphigoid (BP) are among the most prevalent representative AIBDs. Traditional treatments involving corticosteroids and immunosuppressive agents are often associated with substantial adverse effects and a high rate of relapse. In recent years, the therapeutic landscape has evolved toward precision targeted therapies, encompassing biological agents, small-molecule drugs, and chimeric autoantibody receptor T cells. These novel interventions act on specific pathogenic targets, offering the potential to improve both efficacy and safety. This narrative review aims to summarize the latest progress in targeted therapies for PV and BP, compare the mechanisms of action, efficacy, and safety profiles of various treatments, and highlight current challenges and future research directions. In addition, therapeutic considerations for patients with concomitant psoriasis are discussed, given the increasing recognition of this comorbidity in clinical practice and the growing number of case reports describing the use of targeted agents in this specific population. Ultimately, the insights presented herein are intended to optimize clinical management strategies and guide future drug development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PemphigusPemphigoid, BullousMolecular Targeted TherapyHumansImmunosuppressive AgentsAnimalsAutoantibodies

Stichwörter der Autor:innen

CAAR-T therapybiological agentbullous pemphigoidpemphigus vulgarissmall-molecule drugtargeted therapy

Substanzen

Immunosuppressive AgentsAutoantibodies

Autor:innen und Institutionen

  • Department of Dermatology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China.
  • Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100005, China.

ORCID-Profile: Ya-Gang Zuo

Zitieren

APA

Mo, W. F., & Zuo, Y. G. (2026). Research Progress on Targeted Therapies for Pemphigus Vulgaris and Bullous Pemphigoid: Mechanisms, Opportunities and Challenges. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27198779

Vancouver

Mo WF, Zuo YG. Research Progress on Targeted Therapies for Pemphigus Vulgaris and Bullous Pemphigoid: Mechanisms, Opportunities and Challenges. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27198779

BibTeX
@article{Mo2026,
  author = {Mo, Wang-Fei and Zuo, Ya-Gang},
  title = {Research Progress on Targeted Therapies for Pemphigus Vulgaris and Bullous Pemphigoid: Mechanisms, Opportunities and Challenges},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  doi = {10.3390/ijms27198779}
}
Kostenlos starten →